Non-small cell lung cancer, early stage

ABSTRACT Background The Lungscape project aims at building a virtual biobank to facilitate an international high-quality analysis of large numbers of tumors for molecular alterations linked to clinical and biological characteristics captured in the iBiobank. Methods Retrospective radically resected stage I-III non-small cell lung cancer cases from 15 ETOP centers, with mandatory comprehensive clinical annotations including at least 2 years of FU have been reviewed and captured. Results This first set of 1614 cases was enriched in adenocarcinoma (61.8%), with 28.8% of squamous and 4.9% of large cell histologies. Median age is 65 yrs, 37.6% are women, and respectively 13.9%, 33.5% and 49.6% are never, current and former smokers. Stage distribution is: IA 23.7%, IB 25.8%, IIA 16.4%, IIB 11.6%, IIIA 20.8%, IIIB 1.7%. At last FU, 52.8% of patients were still alive, with a median FU of 5.3 yrs. PFS No. of patients 5 years (95% C.I.) Median (mos) (95% C.I.) TOTAL 1614 46 (43.3, 48.6) 49.0 ( 43.9, 55.2) Stage Ia 382 64.5 (59.1, 60.5) NR Ib 417 55.4 (50.3, 60.5) 78.0 IIa 264 44.8 (38.4, 51.3) 46.9 IIb 187 39.2 (31.6, 46.8) 33.7 IIIa 335 20.0 (15.2, 24.8) 17.5 IIIb 28 11.9 (0.0, 25.3) 10.1 OS 1614 52.0 (49.3, 54.7) 64.2 (57.3, 76.9) Stage Ia 382 70.0 (64.9, 75.2) NR Ib 417 60.6 (55.5, 65.7) NR IIa 264 50.5 (43.8, 57.1) 62.2 IIb 187 43.7 (36.0, 51.4) 43.3 IIIa 335 29.3 (23.9, 34.7) 29.0 IIIb 28 10.3 (0.0, 27.1) 20.2 Conclusion This is the first large-scale series based on 7th TNM classification reporting on OS and PFS in the context of European standards of care. These data confirm the discriminative capacity of the 7th TNM with a potentially somewhat superior outcome. Histologies other than adenocarcinoma are currently actively being captured. Complete data including PFS and TTP - never reported before - as well as OS based on the expected 2400 patients correlated to stage, gender, smoking status, histology and age will be provided. This complete clinical dataset will be invaluable to investigate the impact of molecular characteristics on outcome. It will allow building future hypothesis for prospective evaluation of new treatment strategies and help in the development of a molecularly refined TNM. Disclosure All authors have declared no conflicts of interest.